Russell Investments Group, Ltd. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.

Quarter-by-quarter ownership
Russell Investments Group, Ltd. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2023$675,488
-31.9%
61,075
-17.2%
0.00%
-50.0%
Q1 2023$991,213
+29.9%
73,806
+19.7%
0.00%0.0%
Q4 2022$762,833
+0.4%
61,668
+12.9%
0.00%0.0%
Q3 2022$760,000
+12.8%
54,603
+11.7%
0.00%
+100.0%
Q2 2022$674,000
-22.3%
48,886
-8.4%
0.00%
-50.0%
Q1 2022$867,000
-22.6%
53,385
-22.5%
0.00%0.0%
Q4 2021$1,120,000
-2.0%
68,845
-10.6%
0.00%0.0%
Q3 2021$1,143,000
-28.0%
77,037
-3.1%
0.00%
-33.3%
Q2 2021$1,587,000
+37.2%
79,483
+58.3%
0.00%
+50.0%
Q1 2021$1,157,000
-61.4%
50,206
-58.7%
0.00%
-66.7%
Q4 2020$2,998,000
-60.8%
121,441
-34.1%
0.01%
-62.5%
Q3 2020$7,639,000
+280.8%
184,213
+339.6%
0.02%
+300.0%
Q2 2020$2,006,000
+60.6%
41,903
+111.0%
0.00%
+33.3%
Q1 2020$1,249,000
-50.9%
19,860
-3.4%
0.00%
-40.0%
Q4 2019$2,546,000
+111.5%
20,561
+13.3%
0.01%
+150.0%
Q3 2019$1,204,000
+60100.0%
18,154
+60413.3%
0.00%
Q4 2017$2,0000.0%300.0%0.00%
Q3 2017$2,000
-99.9%
30
-99.8%
0.00%
-100.0%
Q2 2017$1,706,000
+2.7%
14,092
-4.0%
0.00%0.0%
Q1 2017$1,661,000
+16.2%
14,683
+12.2%
0.00%0.0%
Q4 2016$1,429,00013,0830.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders